A deep learning model may be able to outperform ophthalmologists in predicting neovascular age-related macular degeneration (nAMD) recurrence. Recurrence of neovascular age-related macular ...

BARCELONA, Spain — Patients who receive a diagnosis of neovascular age-related macular degeneration (nAMD) from their primary care clinician may be less likely to adhere to treatment than those who ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end1 Over 60% of ...

Most patients losing assistance transitioned from on-label anti-VEGF agents to bevacizumab, while a minority maintained original biologics via secondary insurance, samples, or out-of-pocket payment.

Optometrists' ability to classify retinal lesions for re-treatment decisions regarding quiescent neovascular age-related macular degeneration (nAMD) is not inferior to that of ophthalmologists, ...

In the latest stride toward combating neovascular age-related macular degeneration (nAMD), a team led by Professor Nathan Gianneschi from the International Institute for Nanotechnology at Northwestern ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Evaluations of second-generation anti-vascular ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The high number of clinical visits needed to monitor and ...

New research examined the effects of cataract surgery on visual acuity and disease activity in patients with nAMD receiving anti-VEGF treatment. The treatment intensity for underlying nAMD remained ...

Roche voluntarily recalled Susvimo’s ocular implant, insertion tool, and initial fill kit when test results did not satisfy company standards. Following FDA’s approval of a post-approval supplement to ...